Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu

Cell Biology and Toxicology

Volumn 24, Issue 1, 2008, Pages 1-10

  Shiu, L Y ^a   Liang, C H ^b   Huang, Y S ^a   Sheu, H M ^c   Kuo, K W ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d Research Center of Herbal Medicines   (Taiwan)

Author keywords

5 Fluorouracil; Cisplatin; HER2 neu; Methotrexate; Solamargine; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; MEMBRANE PROTEIN; METHOTREXATE; SOLAMARGINE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, SOUTHERN; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RADIOIMMUNOASSAY; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOLANACEOUS ALKALOIDS;

SOLANUM INCANUM;

EID: 37749030574     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-007-9010-5     Document Type: Article

References (30)

1. Alaoui-Jamali MA, Paterson J, Al Moustafa AE, Yen L. The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 1997;75:315-25.
2. Chang LC, Tsai TR, Wang JJ, Lin CN, Kuo KW. The rhamnose moiety of solamargine plays a crucial role in triggering cell death by apoptosis. Biochem Biophys Res Commun 1998;242:21-5.
3. Gebauer G, Mirakhur B, Nguyen Q, Shore SK, Simpkins H, Dhanasekaran N. Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells. Int J Oncol 2000;16:321-5.
4. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-85.
5. 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963;89:114-23.
6. Hager G, Cacsire-Castillo Tong D, et al. The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection. Gynecol Oncol 2005;98:211-6.
7. Hengstler JG, Lange J, Kett A, et al. Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-14.
8. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999;26:51-9.
9. Järvinen TAH, Liu ET. HER-2/neu and topoisomerase IIα in breast cancer. Breast Cancer Res Treat 2003;78:299-311.
10. Järvinen TAH, Tanner M, Rantanen V, Bärlund M, Borg Å, Grénman S. Amplification and deletion of topoisomerase IIα gene are common in ErbB-2 amplified breast cancer and alter the sensitivity to doxorubicin. Am J Pathol 2000;156:839-47.
11. Kammerer U, Thanner F, Kapp M, Dietl J, Sutterlin M. Expression of tumor markers on breast and ovarian cancer cell lines. Anticancer Res 2003;23:1051-5.
12. Keir M, Fiddes R, Biggs JC, Kearney PP. Sensitivity of c-erbB positive cells to a ligand toxin and its utility in purging breast cancer cells from peripheral blood stem cell (PBSC) collections. Stem Cells 2000;18:422-7.
13. Kuo KW, Hsu SH, Li YP, et al. Anticancer activity evaluation of the solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochem Pharmacol 2000;60:1865-73.
14. Liang CH, Liu LF, Shiu LY, Huang YS, Chang LC, Kuo KW. Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells. Biochem Biophys Res Commun 2004;322:751-58.
15. Lin CN, Lu CM, Cheng MK, Gan KH, Won SJ. The cytotoxic principles of Solanum incanum. J Nat Prod 1990;53:513-6.
16. Liu LF, Liang CH, Shiu LY, Lin WL, Lin CC, Kuo KW. Action of solamargine on human lung cancer cells-enhancement of the susceptibility of cancer cells to TNFs. FEBS Lett 2004;577:67-74.
17. Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19: 329-35.
18. Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM. Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 1999;84:354-9.
19. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537-47.
20. Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology 2001;61:73-82.
21. Piechocki MP, Pilon SA, Wei WZ. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods 2002;259:33-42.
22. Roh H, Hirose CB, Boswell CB, Pippin JA, Drebin JA. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery 1999;126:413-21.
23. Sakaguchi A, Kikuchi A. Functional compatibility between isoform α and β of type II DNA topoisomerase. J Cell Sci 2004;117:1047-54.
24. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28:13-9.
25. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 1997;15: 953-60.
26. Untch M, von Koch F, Kahlert S, Konecny G. Overview of epirubicin-based adjuvant therapy in breast cancer. Clin Breast Cancer 2000;1:S41-5.
27. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1999;84:129-34.
28. Yang W, Klos KS, Zhou X, et al. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer 2003;98:1123-30.
29. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996;13:1359-65.
30. Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003;97:1758-65.